Effectiveness of a Triple Antiarrhythmic Drug Strategy for Arrhythmia Recurrence after Persistent Atrial Fibrillation Ablation.

IF 1.7 4区 医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pace-Pacing and Clinical Electrophysiology Pub Date : 2024-10-09 DOI:10.1111/pace.15083
Shuyu Jin, Haowei Chen, Xianhong Fang, Hongtao Liao, Xianzhang Zhan, Lu Fu, Junrong Jiang, Xingdong Ye, Huiyi Liu, Yanlin Chen, Sijia Pu, Shulin Wu, Hai Deng, Weidong Lin, Yumei Xue
{"title":"Effectiveness of a Triple Antiarrhythmic Drug Strategy for Arrhythmia Recurrence after Persistent Atrial Fibrillation Ablation.","authors":"Shuyu Jin, Haowei Chen, Xianhong Fang, Hongtao Liao, Xianzhang Zhan, Lu Fu, Junrong Jiang, Xingdong Ye, Huiyi Liu, Yanlin Chen, Sijia Pu, Shulin Wu, Hai Deng, Weidong Lin, Yumei Xue","doi":"10.1111/pace.15083","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and objective: </strong>Treating recurrent atrial arrhythmias after persistent atrial fibrillation (PeAF) ablation is often challenging. This single-center, prospective study aimed to observe the effectiveness of different combinations of oral antiarrhythmic drugs (AADs) in reverting to sinus rhythm (SR) in patients with recurrent atrial arrhythmias after PeAF ablation.</p><p><strong>Methods: </strong>Forty-five patients who experienced recurrent atrial arrhythmias after PeAF ablation were included. Based on their medication regimens, patients were divided into two groups, with the study group being a triple-drug group (digoxin combined with amiodarone/ propafenone and β-blocker), and the control group being a non-triple-drug group.</p><p><strong>Results: </strong>The rate of reversion to SR was significantly higher in the study group (n = 29) than in the control group (n = 16) at 3 weeks (34.48% vs. 0%, p < 0.01) and 1 month (44.84% vs. 6.25%, p = 0.02) after initiating AADs. No patients with asymptomatic bradycardia were observed in either group.</p><p><strong>Conclusions: </strong>For patients with recurrent atrial arrhythmias after PeAF ablation, a regimen of low-dose digoxin combined with amiodarone/propafenone and β-blocker may effectively improve short-term reversion rates.</p>","PeriodicalId":54653,"journal":{"name":"Pace-Pacing and Clinical Electrophysiology","volume":null,"pages":null},"PeriodicalIF":1.7000,"publicationDate":"2024-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pace-Pacing and Clinical Electrophysiology","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.1111/pace.15083","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Background and objective: Treating recurrent atrial arrhythmias after persistent atrial fibrillation (PeAF) ablation is often challenging. This single-center, prospective study aimed to observe the effectiveness of different combinations of oral antiarrhythmic drugs (AADs) in reverting to sinus rhythm (SR) in patients with recurrent atrial arrhythmias after PeAF ablation.

Methods: Forty-five patients who experienced recurrent atrial arrhythmias after PeAF ablation were included. Based on their medication regimens, patients were divided into two groups, with the study group being a triple-drug group (digoxin combined with amiodarone/ propafenone and β-blocker), and the control group being a non-triple-drug group.

Results: The rate of reversion to SR was significantly higher in the study group (n = 29) than in the control group (n = 16) at 3 weeks (34.48% vs. 0%, p < 0.01) and 1 month (44.84% vs. 6.25%, p = 0.02) after initiating AADs. No patients with asymptomatic bradycardia were observed in either group.

Conclusions: For patients with recurrent atrial arrhythmias after PeAF ablation, a regimen of low-dose digoxin combined with amiodarone/propafenone and β-blocker may effectively improve short-term reversion rates.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
三联抗心律失常药物策略对持续性心房颤动消融术后心律失常复发的疗效。
背景和目的:治疗持续性心房颤动(PeAF)消融术后复发的房性心律失常通常具有挑战性。这项单中心前瞻性研究旨在观察不同口服抗心律失常药物(AADs)组合对 PeAF 消融术后复发性房性心律失常患者恢复窦性心律(SR)的有效性:方法:纳入 45 例 PeAF 消融术后复发房性心律失常的患者。研究组为三联药物组(地高辛联合胺碘酮/普罗帕酮和β-受体阻滞剂),对照组为非三联药物组:3周后,研究组(29 人)的 SR 恢复率明显高于对照组(16 人)(34.48% 对 0%,P 结论:研究组的 SR 恢复率明显高于对照组(34.48% 对 0%,P 结论:研究组的 SR 恢复率明显高于对照组(34.48% 对 0%,P 结论):对于 PeAF 消融术后复发房性心律失常的患者,小剂量地高辛联合胺碘酮/丙帕酮和β-受体阻滞剂可有效提高短期转复率。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Pace-Pacing and Clinical Electrophysiology
Pace-Pacing and Clinical Electrophysiology 医学-工程:生物医学
CiteScore
2.70
自引率
5.60%
发文量
209
审稿时长
2-4 weeks
期刊介绍: Pacing and Clinical Electrophysiology (PACE) is the foremost peer-reviewed journal in the field of pacing and implantable cardioversion defibrillation, publishing over 50% of all English language articles in its field, featuring original, review, and didactic papers, and case reports related to daily practice. Articles also include editorials, book reviews, Musings on humane topics relevant to medical practice, electrophysiology (EP) rounds, device rounds, and information concerning the quality of devices used in the practice of the specialty.
期刊最新文献
Coronary Spasm Due to Pulsed Field Ablation: A State-of-the-Art Review. Recalled But Responsive: Easier Extraction of Recalled Leads. Vein of Marshall Ethanol Infusion: Beware the Left Atrial Appendage Isolation. Changes in QRS morphology during antidromic atrioventricular reentrant tachycardia. Exercise-induced type 1 Brugada pattern in a child.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1